Sera Prognostics, Inc.
NASDAQ:SERAMedical - Diagnostics & Research
-$0.03 today
- Market cap
- $74.11M
- Beta
- 0.94
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.64
Volume 0.01M
Average 0.06M
SERA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Sera Prognostics, Inc.NASDAQ: SERA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $193K fell 10.6% year over year, behind the +9.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 20.9% from the prior quarter. Over 3 fiscal years it compounded at +7.5% a year.
Context
- Depreciation & amortization amounted to 1160.5% of revenue in FY2025, up 78.7 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -10.6% toward the trailing-twelve-month pace of +9.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 940K USD
- Year-over-year change
- +12.8%
- 4-year CAGR
- +9.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 940K | +12.8% |
| FY2024 | 2024-12-31 | 833K | -7.4% |
| FY2023 | 2023-12-31 | 900K | +19.0% |
| FY2022 | 2022-12-31 | 756K | +14.7% |
| FY2021 | 2021-12-31 | 659K | — |
Depreciation & Amortization vs competitors
How SERA compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +9.7% is the 3rd highest of 8, against a peer median of -8.6%.
- Depreciation & amortization amounts to 1608.8% of revenue for SERA, versus a peer median of 6.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $429.44M USD | +48315.3% | -23.3% | 8364.7% | |
| LTM Mar 2026 | $3.11M USD | -8.6% | +4.7% | 9.0% | |
| LTM Mar 2026 | $917K USD | +9.7% | +7.5% | 1608.8% | |
| LTM Mar 2026 | $719K USD | +24.0% | -9.7% | 1.3% | |
| LTM Mar 2026 | $308K USD | -77.1% | -35.0% | 4.1% | |
| LTM Mar 2026 | $251K USD | -0.8% | -1.0% | — | |
| LTM Mar 2026 | $80.68K USD | — | -42.4% | — | |
| LTM Mar 2026 | CA$75.25K CAD | -81.1% | -37.4% | — | |
| LTM Mar 2026 | $23.95K USD | -96.6% | -41.3% | 6.0% | |
| Peer median (excluding SERA) | — | -8.6% | -29.2% | 6.0% | |
Competitors are the stored peer set for SERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (35.01M) | (44.19M) | (36.24M) | (32.9M) | (31.93M) |
| Depreciation & Amortization | 659K | 756K | 900K | 833K | 940K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.13M | 5.06M | 5.27M | 7.01M | 5.11M |
| Change in Working Capital | (44K) | 3.55M | 3.52M | 11.28M | (546K) |
| Accounts Receivables | (3.14M) | (2.97M) | (5.36M) | 11.42M | 22K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 603K | 352K | (442K) | 455K | (1.01M) |
| Other Working Capital | 2.49M | 6.17M | 9.32M | (597K) | 441K |
| Other Non-Cash Items | (372K) | 213K | (638K) | (412K) | 801K |
| Operating Cash Flow | (31.64M) | (34.61M) | (27.19M) | (14.19M) | (25.62M) |
| Capital Expenditures | (1.3M) | (791K) | (128K) | (1.1M) | (726K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (82.06M) | (48.07M) | (54.14M) | (35.83M) | (87.61M) |
| Sales of Investments | 800K | 54.4M | 54.4M | 48.68M | 59.84M |
| Other Investing Activities | 0 | 16K | 311K | (1.05M) | 0 |
| Investing Cash Flow | (82.56M) | 5.55M | 438K | 11.74M | (28.5M) |
| Debt Repayment | (7.66M) | (303K) | (466K) | (440K) | (194K) |
| Common Stock Issued | 66.61M | 0 | 0 | 0 | 54.22M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.66M | 308K | 1.22M | 3.05M | 0 |
| Financing Cash Flow | 159.59M | 5K | 752K | 2.61M | 54.03M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 45.4M | (29.05M) | (26M) | 163K | (99K) |
| Free Cash Flow | (32.94M) | (35.4M) | (27.32M) | (15.29M) | (26.35M) |
Sera Prognostics, Inc.
NASDAQ:SERA
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.